Page last updated: 2024-12-05

carbromal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

carbromal: was heading 1963-94 (Prov 1963-73); use UREA to search CARBROMAL 1963-94 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6488
CHEMBL ID1697828
CHEBI ID134961
SCHEMBL ID261
MeSH IDM0225268

Synonyms (99)

Synonym
nsc49191
nsc-49191
n-(aminocarbonyl)-2-bromo-2-ethylbutanamide
carbromal (inn)
adalin (tn)
D02619
parkosed
karbromal
pianadalin
hoggar
(.alpha.-bromo-.alpha.-ethylbutyryl)carbamide
bromadel
planadalin
77-65-6
uradal
tildin
2-bromo-2-ethylbutyrylurea
dormiturin
nci-c03805
carbromal
kartryl
bromadal
urea, (2-bromo-2-ethylbutyryl)-
bromodiethylacetylurea
nyctal
1-bromo-ethyl-butyryl-urea
pelidorm
diacid
addisomnol
.alpha.-ethyl-.alpha.-bromobutyrylurea
(.alpha.-bromo-.alpha.-ethylbutyryl)urea
butanamide, n-(aminocarbonyl)-2-bromo-2-ethyl-
nenesin
nsc9916
bromdiethylacetylurea
bromacetocarbamide
adalin
wln: zvmvxe2&2
urea, (2-bromo-ethylbutyryl)-
bromodiethylacetylcarbamide
fydalin
nsc-9916
hsdb 4100
(2-brom-2-ethylbutyryl)harnstoff
(alpha-bromo-alpha-ethylbutyryl)urea
ccris 124
ai3-51262
persomnin
brn 1775637
(2-bromo-2-ethylbutyryl)urea
(alpha-bromo-alpha-ethylbutyryl)carbamide
nsc 49191
2-brom-2-ethylbutyrylmocovina [czech]
einecs 201-046-6
bromacetocarbamidum
thalambrol
mirfudorm
alpha-ethyl-alpha-bromobutyrylurea
servadorm
somben
carbromalum [inn-latin]
CHEBI:134961
2-bromo-n-carbamoyl-2-ethylbutanamide
2-bromo-2-ethylbutyryurea
CHEMBL1697828
carbromal [inn:ban:dcf:nf]
0y299jy9v3 ,
carbromalum
2-brom-2-ethylbutyrylmocovina
unii-0y299jy9v3
cas-77-65-6
NCGC00255200-01
dtxsid8020252 ,
tox21_302247
dtxcid80252
FT-0623490
SCHEMBL261
carbromal [who-dd]
carbromal [hsdb]
carbromal [mi]
carbromal [inn]
carbromal [mart.]
OPNPQXLQERQBBV-UHFFFAOYSA-N
butanamide, n-aminocarbonyl-2-bromo-2-ethyl-
(.alpha.-ethyl-.alpha.-bromobutyryl)urea
.alpha.-bromo-.alpha.-ethylbutyrylurea
n-(2-bromo-2-ethylbutanoyl)urea #
adisomnol
J-803001
dtpm reagent
n-(2-bromo-2-ethylbutanoyl)urea
AKOS027383909
SR-01000883968-1
sr-01000883968
Q382185
p-nitrophenylstearate
DB13817
adalin; adisomnol; bromacetocarbamide; bromadal
(2-bromo-2-ethylbutanoyl)urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
N-acylureaA member of the class of ureas that has the general formula R-CO-NH-CO-NH2 or R-CO-NH-CO-NH-CO-R', formally derived by the acylation of one or both of the nitrogens of a urea moiety.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency68.58960.001022.650876.6163AID1224838
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199026 (96.30)18.7374
1990's0 (0.00)18.2507
2000's1 (3.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 39.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index39.00 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index56.46 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (39.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]